OBJECTIVES: To perform SR with MA of all randomized controlled trials (RCT) comparing the effi cacy of BEV-CT versus CT alone in previously untreated locally advanced or metastatic NSCLC. METHODS: We searched MEDLINE, EMBASE, LILACS, and CENTRAL among others. Primary end points were overall survival (OS) and progression-free survival (PFS). Adverse events (AE) were analyzed. Extracted data were combined using hazard ratio (HR) or risk ratio (RR) with 95% confi dence intervals (CI 95%). RESULTS: 544 references were identifi ed and screened, three trials comprising 2020 patients were included. Overall response rate (RR = 0.53; CI 95% = 0.44 to 0.64; P < 0.00001) and PFS were higher in BEV-CT (HR = 0.71, CI 95% = 0.63 to 0.80; P < 0.00001), however with signifi cant heterogeneity (χ 2 = 4.9, df = 2 [P = 0.09]; I 2 = 59%) and (χ 2 = 4.33, df = 2 [P = 0.11]; I 2 = 54%), respectively. Random-efffects model analysis favored BEV-CT. OS was higher in BEV-CT but with signifi cant heterogeneity (χ 2 = 5.92, df = 3 [P = 0.12]; I 2 = 49%) and random-effects model analysis was not statistically signifi cant (HR = 0.86, CI 95% = 0.71 to 1.05; P = 0.15). Neutropenia (RR = 0.77; CI 95% = 0.65 to 0.91; P = 0.002) and febrile neutropenia (RR = 0.42; CI 95% = 0.22 to 0.81; P = 0.009) were higher on BEV-CT. Rates of anemia (RR = 1.41; CI 95% = 0.93 to 2.13; P = 0.1) and thrombocytopenia (RR = 0.91; CI 95% = 0.69 to 1.20; P = 0.50) were similar. Non-hematologic toxicities were higher on BEV-CT: hemoptysis (RR = 0.28; CI 95% = 0.09 to 0.90; P = 0.03), hypertension (RR = 0.15; CI 95% = 0.07 to 0.30; P < 0.00001), proteinuria (RR = 0.05; CI 95% = 0.01 to 0.41; P = 0.005), venous thromboembolic events (RR = 0.87; CI 95% = 0.51 to 1.47; P = 0.6), vomiting (RR = 0.41; CI 95% = 0.22 to 0.77; P = 0.005), rash (RR = 0.19; CI 95% = 0.04 to 0.88; P = 0.03), epistaxis (RR = 0.32; CI 95% = 0.03 to 3.10; P = 0.33) and bleeding events (RR = 0.27; CI 95% = 0.13 to 0.56; P = 0.0004). CONCLUSIONS: The combination BEV-CT increased the response rate and PFS in patients with NSCLC. Benefi ts in overall survival remain uncertain, and toxicity rates were higher in the combination group.
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REAL-WORLD COST-EFFECTIVENESS OF OXALIPLATIN IN STAGE III COLON CANCER: A SYNTHESIS OF TRIAL DATA WITH DATA FROM DAILY CLINICAL PRACTICE
van Gils C, de Groot S, Redekop W, Uyl-de Groot C Erasmus University, Rotterdam, The Netherlands OBJECTIVES: Previous cost-effectiveness analyses of oxaliplatin have been based on randomized trial settings which may not refl ect actual daily practice. The objective of this study was to examine the real-world cost-effectiveness of oxaliplatin plus fl uoropyrimidines versus fl uoropyrimidines only, as adjuvant treatment of colon cancer. METHODS: A Markov model was developed to estimate lifetime costs and qualityadjusted life-years (QALYs) from a hospital perspective. Dutch real-world (RW) population-based data on use, costs, and disease-free survival after oxaliplatin use were combined with published effi cacy data from the pivotal clinical registration trial (MOSAIC trial). Eighty-two percent of the patients in the RW study fulfi lled the MOSAIC trial eligibility criteria ("eligibles"); the other 18% ("ineligibles") had a poorer prognosis. The effi cacy of the comparator was modelled using MOSAIC trial results. Cost-effectiveness analyses (CEAs) were performed for four different scenarios: 1) CEA based on MOSAIC trial patients; 2) CEA using eligible RW patients; 3) CEA using both eligibles and ineligibles, assuming that oxaliplatin had an equal effect in both groups; and 4) CEA using eligibles and ineligibles, assuming oxaliplatin had no effect among ineligibles. RESULTS: MOSAIC and eligible RW patients had similar 2-year disease-free survivals (79% vs. 78%). Oxaliplatin showed an incremental QALY gain of 0.86, 0.73, 0.81, and 0.60, and incremental costs of c13,105, c13,278, c13,225, and c13,456 in scenarios 1 to 4, respectively. The corresponding incremental cost-effectiveness ratios (ICERs) were c15,185, c18,115, c16,254, and c22,387 in scenarios 1 to 4, respectively. Sensitivity analyses of input parameters and model assumptions produced only minimal differences in the estimated ICERs showing the robustness of the model results. CONCLUSIONS: The real-world cost-effectiveness of oxaliplatin plus fl uoropyrimidine versus fl uoropyrimidine for the treatment of colon cancer can be estimated using different scenarios. We found that the various estimates were very similar, and all suggest that oxaliplatin is cost-effective.
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COST OF ABSENTEEISM DUE TO CANCER IN POLAND
Macioch T 1 , Hermanowski T 1 , Adamowicz O 2 1 Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland; 2 HealthQuest sp.z o.o., Warsaw, Poland OBJECTIVES: Cancer is a leading cause of death worldwide and major health problem. It's also a huge problem to worldwide economy due to high both direct and indirect costs. The aim of this study was to evaluate absenteeism costs of cancer in Poland in 2007. METHODS: Sickness absence data and data on disability were derived by ZUS (Social Insurance Institution). Costs of lost productivity due to premature death were estimated based on regional register data on cancer mortality (KRN-National Cancer Registry). Absenteeism costs were estimated based on gross value added per employee derived by Central Statistical Offi ce (GUS). The analyses of indirect costs due to sickness absence were based on an assumption that number of missed days includes only working days (226 days per year). Human capital approach was used to estimate the absenteeism costs. Values are presented in Euro (exchange rate: 1 EUR = 4.10 PLN). RESULTS: Costs of lost productivity due to illness and disability were estimated to amount of c1081 million (c451 and c630 million, respectively). Costs of lost productivity due to premature death were estimated to amount of c4692 million and were twice as high in male population compare to female population (c3200 and c1492 million, respectively). The highest costs of lost productivity due to premature death were related to lung cancer (c1331 million) followed by brain (c356 million), stomach (c314 million), and breast cancer (c259 million). Lung cancer was the leading cost of lost productivity due to premature death in male population (c917 million), while breast cancer dominated in female population (c255 million). CONCLUSIONS: Indirect costs of lost productivity due to cancerrelated illness, disability, and premature death are substantial to polish economy and may account for near 0.6% of PKB loss in 2007 year.
